摘要
评价泛昔洛韦治疗带状疱疹的安全有效性。方法：本试验组１３５例，对照组 １１１例可评价疗效。给药方法随机开放，泛昔洛韦为试验药 ２５０ｍｇ，口服。每日三次，阿昔洛韦为对照药 ２００ｍｇ，每日五次，两药均 ７ｄ，分别在服药后 ４，８，１５，２２和２９日随访观察主要症状和皮损变化。结果：试验组和对照组分别有１７例（１２．６％）和１５例（１３．５％）服药后有新水疱出现，水疱数目开始减少平均日数两组分别为３．２２ ±１．４５， ３．９３ ± ２．５２；水疱消退两组平均日数分别为７．３９ ± ４．５３， ９．０４±５．６２，结痂开始两组平均日数分别为３．０８±１．７０，４．１６±３．３４全部脱痂两组平均日数为１３．９３±６．４６，１５．７３ ± ７．６１，两组统计学处理有显著差异（Ｐ＜０．０５）。疼痛消失率试验组和对照组在治疗后８， １５， ２９日时分别为６３．７％，４１．１％； ８５．９％， ５８．６％；９５．６％，８７．４％。两组比较有差异（Ｐ＜０．０１）。药物不良反应主要有头痛、头晕，两组分别为３．０％和２．７％；恶心、呕吐两组分别为３．０％和３．６％，两组比较无差异。两组均有少数病例用药后尿中红细胞，血中ＡＬＴ及ＢＵＮ增高，但无?
OBJECTIVE: To evaluate the safety and efficacy of famcicovir in the treatment of herpes zoster. METHODS : A multicenter randomized controlled clinical study of famciclovir was conducted compared with acyclovir,135 patients in test group received famciclovir 250mg by oral administration, three times a day and 111 patients in control group received acyclovir 20mg by oral administration,five times a day. The duration of treatment was seven days in both groups. RESULTS: The results showed that new vesciles appeared in 17 cases(12.6%)and 15 cases (13.5%)after treatment in both groups respectively. The mean days of vesciles were reduced 3.22 ±1 .45and 3.93 ±2.52 days. All days vesciles disappeared in 7.39 ±4.53and 9.04 ±5.62 days in both groups respectively. The mean days of crust were 3.08 ±1 .70 and 4.16 ±3.34 days. All crust disappeared in 13.93 ± 6.46and 15.73 ±7.61 days in both groups respectively. There were statistical differences between two groups(P < 0.05). The rate of pain disappeared were 63.7%. 41. 1 %, 85.9%, 58.6%, 95.6% and 87.4% after treatment in 8, 15 and 29 days between two groups respectively .There were statistical differences between two groups (P < 0.01).Both treatment were equally well tolerated. CONCLUSION: famciclovir has a good safety and efficacy for the treatment of herpes zoster.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2000年第4期269-271,共3页
The Chinese Journal of Clinical Pharmacology
